BiotechTube

Cefiderocol + Standard of Care Antibiotic

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bacterial Pneumonia

Conditions

Bacterial Pneumonia

Trial Timeline

Feb 20, 2019 → Oct 15, 2019

NCT ID
NCT03862040

About Cefiderocol + Standard of Care Antibiotic

Cefiderocol + Standard of Care Antibiotic is a phase 1 stage product being developed by Shionogi for Bacterial Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03862040. Target conditions include Bacterial Pneumonia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03862040Phase 1Terminated

Competing Products

20 competing products in Bacterial Pneumonia

See all competitors
ProductCompanyStageHype Score
ASP3652 + PlaceboAstellas PharmaPhase 2
52
Cefiderocol + Standard of CareShionogiPhase 2
52
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
33
Cefiderocol + Standard of CareShionogiPhase 2
52
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
33
Xeruborbactam + Cefiderocol + Xeruborbactam/Cefiderocol + Dextrose 5% in waterShionogiPhase 1
33
CefiderocolShionogiPre-clinical
23
Cefiderocol + Standard of CareShionogiPhase 2
52
Cefiderocol/XeruborbactamShionogiPhase 1
33
DoripenemJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved
85
doripenemJohnson & JohnsonPhase 3
77
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
HRS-8427Jiangsu Hengrui MedicinePhase 1
33
Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4AbbViePhase 2
52
DalbavancinAbbViePhase 1
33
V419 + INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad™MerckPhase 3
77
AzaSite + TobramycinMerckPhase 3
77
AzaSiteMerckPhase 3
77

Other Products from Shionogi

Naldemedine + PlaceboApproved
85
Rosuvastatin + HMG CoA inhibitorApproved
85
StatinApproved
85
CefiderocolApproved
85
Duloxetine + Pregabalin + PlaceboApproved
85